99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Molecular Insight Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT01654874
First received: July 30, 2012
Last updated: June 7, 2013
Last verified: June 2013

July 30, 2012
June 7, 2013
July 2012
February 2013   (final data collection date for primary outcome measure)
To assess the image quality of a simplified kit formulation of 99mTc-MIP-1404 (study drug) compared to a multi-step preparation of 99mTc-MIP-1404 in patients with confirmed metastatic prostate adenocarcinoma and in healthy volunteers [ Time Frame: Whole-body planar scintigraphic images will be acquired at 30 min, 2 and 4 hours post administration. A pelvic SPECT/CT image will be acquired at 3 hours post study drug administration ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01654874 on ClinicalTrials.gov Archive Site
To determine the pharmacokinetics, biodistribution and tumor uptake of 99mTc-MIP-1404 preparations in patients with confirmed metastatic prostate adenocarcinoma and in healthy volunteers [ Time Frame: Blood will be collected for PK and radioactivity counting at baseline, 2 minutes, 5 minutes, 30 minutes, 1 hour, 2 hours, and 4 hours post study drug administration. ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404
99mTc-MIP-1404 for Imaging Prostate Cancer: Phase I Clinical Study to Assess the Image Quality of a Simplified Kit Formulation Compared to a Multi-step Preparation of 99mTc-MIP-1404

This trial is a single-blind, cross-over design. Up to three patients with confirmed metastatic prostate adenocarcinoma and up to three healthy volunteers will receive two doses of 20.0 (± 3) mCi of intravenously administered 99mTc MIP 1404 (preparation A or preparation B). Whole-body planar scintigraphic images will be acquired at various time points on the day of study drug administration. A pelvic SPECT/CT image will be acquired on the day of study drug administration. Blood will be collected for pharmacokinetic measurements following study drug administration. Each participant will receive an initial study drug administration (preparation A) and a second study drug administration (preparation B) approximately 7 to 21 days later. A final follow-up visit will occur approximately 2 - 3 weeks after the second study drug administration.

Not Provided
Interventional
Phase 1
Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: Single Blind (Subject)
Primary Purpose: Diagnostic
Prostate Cancer
Drug: 99mTc-MIP-1404
  • Experimental: Preparation A
    20 (±3) mCi 99mTc-MIP-1404 (preparation A)
    Intervention: Drug: 99mTc-MIP-1404
  • Experimental: Preparation B
    20 (±3) mCi 99mTc-MIP-1404 (preparation B)
    Intervention: Drug: 99mTc-MIP-1404

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
6
Not Provided
February 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male aged 21 years or older.
  • Ability to provide signed informed consent and willingness to comply with protocol requirements.
  • Participants must agree to use an acceptable form of birth control throughout the study period. Participants must agree to use condoms for a period of seven days after each study drug administration, if engaged in sexual activity.

Additional Inclusion Criteria for Metastatic Prostate Adenocarcinoma Patients:

  • Histologic diagnosis of prostate cancer by validated medical history (pathology report, if available).
  • Evidence of metastatic disease demonstrated by a documented abnormal bone scan, CT scan, or MRI
  • Karnofsky performance is ≥ 60

Additional Inclusion Criteria for Healthy Volunteers:

  • PSA laboratory assessment within normal range (PSA < 4 ng/ml)
  • Normal findings on a digital rectal examination
  • Hemoglobin and hematocrit within normal range

Exclusion Criteria:

  • Received a radioisotope within 5 physical half lives of that radioisotope prior to study enrollment
  • Have any medical condition or other circumstances which, in the opinion of the Investigator, would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post dose follow-up examinations
  • Participant is determined by the Investigator to be clinically unsuitable for the study
  • Serum creatinine ≥ 2.0 mg/dl
  • Total bilirubin ≥ 2.0 mg/dl
  • Liver transaminases ≥ 1.5 x ULN
  • Platelet count < 100,000/mm3
  • Absolute neutrophil count (ANC) < 2,000/mm3
  • Hematocrit < 30% or hemoglobin < 10 g/dl

Additional Exclusion Criteria for Metastatic Prostate Adenocarcinoma Patients:

  • Have received a permanent prostate brachytherapy implant within the last 3 months for 103Pd implants; or 12 months for 125I implants
  • Have had any other malignancies within the past year, other than basal or squamous cell carcinoma of the skin, in which the diagnosis and location have not been defined as clinically controlled or treated to complete response
Male
21 Years and older
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01654874
MIP-TcTx-P101b
No
Molecular Insight Pharmaceuticals, Inc.
Molecular Insight Pharmaceuticals, Inc.
Not Provided
Principal Investigator: Stanley J Goldsmith, MD Department of Nuclear Medicine, New York Presbyterian Hospital, Weill Cornell Medical College
Molecular Insight Pharmaceuticals, Inc.
June 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP